A Study of Olaparib and Durvalumab in Prostate Cancer
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
Prostate Cancer
DRUG: Olaparib|DRUG: Durvalumab
Therapeutic Efficacy as Defined by Number of Participants With an Undetectable PSA, To assess the therapeutic efficacy as defined by an undetectable PSA (\<0.05 or PSA \<0.10 for institutions where this is the lower limit of detection) with non-castrate levels of testosterone using the combination olaparib (PARP inhibition) with durvalumab (PDL1 inhibition) at 24 months (cycle 24) in biochemically recurrent prostate cancer, 1 year
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.